Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
WuXi AppTec shows how integrated CRDMO platforms help protein degrader programs reach the clinic by connecting chemistry, biology, and CMC early.
-
Dublin, July 03, 2026 (GLOBE NEWSWIRE) -- The "Crispr-Based Drug Development Platforms Market - Strategic Insights and Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering. ...
-
Drug developers have a new, optimized option for U.S.-based manufacturing, as AGC Biologics enters a strategic partnership with Pyramid Pharma Services.
-
WuXi AppTec details how structural complexity in protein degraders, covalent agents, and kinase programs is reshaping what integrated CRDMOs must deliver.
-
Avance Clinical Announces Asia Pacific and Mainland China Expansion Ahead of BIO International Convention 2026
-
Avance Clinical Announces Asia Pacific and Mainland China Expansion Ahead of BIO International Convention 2026
-
Alison Strutt appointed as Chief Financial Officer, László Tankó appointed as Consultant Chief Medical Officer, and Sam Fazeli appointed Non-Executive DirectorAppointments support MitoRx’s next phase...
-
MTRX31 led to a highly significant decrease in fat mass after two-months chronic dosing in a preclinical diet-induced obesity mouse model performed at thermoneutrality Weight loss and reduction of fat...
-
THE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1...
-
Launch of TechBio firm, Lucera, brings decision intelligence to drug development, making it more predictable, more evidence-grounded, and more efficient Well-established pharmaceutical technology...